Efficacy and safety of adalimumab in Chinese patients with moderate‐to‐severe plaque psoriasis: results from a phase 3, randomized, placebo‐controlled, double‐blind study

Por Cai, L., Gu, J., Zheng, J., Zheng, M., Wang, G., Xi, L.‐Y., Hao, F., Liu, X.‐M., Sun, Q.‐N., Wang, Y., Lai, W., Fang, H., Tu, Y.‐T., Sun, Q., Chen, J., Gao, X.‐H., Gu, Y., Teixeira, H.D., Zhang, J.‐Z., Okun, M.M.
Publicado no J Eur Acad Dermatol Venereol (2016)